Back to today’s briefing

Story perspectives

New Drug Target Could Transform Cancer Treatment for Thousands

7/26/2025

32 4

Summary

Story summary

Virginia Tech researchers have uncovered a promising target for experimental drugs that could inhibit PRMT5, an enzyme linked to tumor growth. By pairing PRMT5 inhibitors with drugs that block the MAP kinase pathway, they aim to enhance treatment for stubborn lung, brain, and pancreatic cancers, potentially aiding 80,000 patients in the U.S. each year.

1 of 1

Story summary

Virginia Tech researchers have uncovered a promising target for experimental drugs that could inhibit PRMT5, an enzyme linked to tumor growth. By pairing PRMT5 inhibitors with drugs that block the MAP kinase pathway, they aim to enhance treatment for stubborn lung, brain, and pancreatic cancers, potentially aiding 80,000 patients in the U.S. each year.